高雄榮民總醫院

皮膚癌(melanoma)診療原則



皮膚癌醫療團隊擬定

Reference: NCCN Clinical Practice Guideline in OncologyTM ,melanoma, V.1.2015

黑色素細胞癌(melanoma)

高雄榮民總醫院
臨床診療指引 2015第一版

診斷	初步評估	分期(附表1)	評估

臨床診斷之可疑病灶，經皮膚切片及病理組織學證實。

1、病史
2、理學檢查
(1)完整皮膚檢查。
(2)淋巴結檢查。
3、黑色素細胞癌危險因子評估
4、實驗室檢查
(1)CBC/DC
(2)Biochemistry(包括LDH)
(3)HBV/HCV
5、初步影像學檢查§
(1)CXR
(2)Regional LNs, echo

Stage 0 (melanma in situ)

1、影像學檢查△
(1)CT
(2)MRI
(3)Gallium scan
(4)Bone scan
(5)PET / CT
2、sentinel LNs biopsy

Stage I
Stage II
Stage III
Stage IV

§： 可選擇

△：建議 whole body PET / CT + brain MRI



黑色素細胞癌(melanoma)

高雄榮民總醫院
臨床診療指引 2015第一版

分期	初步治療(附表2)	輔助治療	再評估	追蹤

Stage 0
(melanma in situ) → **wide excision** → negative

Stage I → **wide excision**

Stage II → **wide excision**

◎

CVD regimen(附表4)
Interferon-α
Ipilmumab
Vemurafenib⁺
Dabrafenib⁺
RT(附表3)

＋ **Restage：**
Brain MRI and PET

negative → **Monthly*III**
↓
Quarterly
Or
Palliative care
(安寧緩和)

If病程持續進展

◎

Stage III → **wide excision + complete LNs dissection**

Stage IV → **wide excision + complete LNs dissection**

Dantmouth regimen(附表5)
Interferon-α
Ipilmumab
Vemurafenib⁺
Dabrafenib⁺
Interleukin-2
Palliative symptom management,
Clinical trial、RT(附表3)
Temozolomide、Palliative surgery

＋ **Restage：**
Brain MRI and PET

◎：可選擇

＋：for BRAF mutation patient



黑色素細胞癌(melanoma)

高雄榮民總醫院
臨床診療指引 2015第一版

復發

1、病史
2、理學檢查
(1)完整皮膚檢查
(2)淋巴結檢查
3、黑色素細胞癌危險因子評估
4、實驗室檢查
(1)CBC/DC
(2)Biochemistry(包括LDH)
(3)HBV/HCV
5、初步影像學檢查§
(1)CXR
(2)Regional LNs, echo

1、影像學檢查△
(1)CT
(2)MRI
(3)Gallium scan
(4)Bone scan
(5)PET / CT
2、sentinel LNs biopsy

Stage 0 (melanma in situ) → wide excision

Stage I → wide excision

Stage II → wide excision

Stage III → wide excision + complete LNs dissection

Stage IV → wide excision + complete LNs dissection

◎
CVD regimen(附表4)
Interferon-α
Ipilmumab
Vemurafenib+
Dabrafenib+
RT(附表5)
＋ Restage：Brain MRI and PET

negative → Monthly*III ↓ Quarterly Or Palliative care (安寧緩和)

if 病程持續進展

◎
Dantmouth regimen(附表5)
Interferon-α
Ipilmumab
Vemurafenib+
Dabrafenib+
Interleukin-2
Palliative symptom management,
Clinical trial、RT(附表3)
Temozolomide、Palliative surgery
＋ Restage：Brain MRI and PET



黑色素細胞癌(melanoma)

高雄榮民總醫院
臨床診療指引 2015第一版

附件一-1:

National Comprehensive Cancer Network®

NCCN Guidelines Version 2.2015 Staging Melanoma

NCCN Guidelines Index
Melanoma Table of Contents
Discussion

Table 1

American Joint Committee on Cancer (AJCC)
TNM Staging System for Melanoma (7th ed., 2010)

Primary Tumor (T)

TX	Primary tumor cannot be assessed (eg, curettaged or severely regressed melanoma)
T0	No evidence of primary tumor
Tis	Melanoma *in situ*
T1	Melanomas 1.0 mm or less in thickness
T2	Melanomas 1.01 – 2.0 mm
T3	Melanomas 2.01 – 4.0 mm
T4	Melanomas more than 4.0 mm

Note: a and b sub categories of T are assigned based on ulceration and number of mitoses per mm^2 as shown below:

T classification	*Thickness (mm)*	*Ulceration Status/Mitoses*
T1	≤1.0	a: w/o ulceration and mitosis $<1/mm^2$ b: with ulceration or mitoses $\geq 1/mm^2$
T2	1.01-2.0	a: w/o ulceration b: with ulceration
T3	2.01-4.0	a: w/o ulceration b: with ulceration
T4	>4.0	a: w/o ulceration b: with ulceration

Regional Lymph Nodes (N)

NX	Patients in whom the regional lymph nodes cannot be assessed (eg, previously removed for another reason)
N0	No regional metastases detected
N1-3	Regional metastases based upon the number of metastatic nodes and presence or absence of intralymphatic metastases (in transit or satellite metastases)

Note: N1-3 and a-c sub categories are assigned as shown below:

N Classification	*No. of Metastatic Nodes*	*Nodal Metastatic Mass*
N1	1 node	a: micrometastasis* b: macrometastasis**
N2	2-3 nodes	a: micrometastasis* b: macrometastasis** c: in transit met(s)/ satellite(s) *without* metastatic nodes
N3	4 or more metastatic nodes, or matted nodes, or in transit met(s)/satellite(s) *with* metastatic node(s)	

*Micrometastases are diagnosed after sentinel lymph node biopsy and completion lymphadenectomy (if performed).

**Macrometastases are defined as clinically detectable nodal metastases confirmed by therapeutic lymphadenectomy or when nodal metastasis exhibits gross extracapsular extension.

Continue

Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original and primary source for this information is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer Science+Business Media, LLC (SBM). (For complete information and data supporting the staging tables, visit www.springer.com.) Any citation or quotation of this material must be credited to the AJCC as its primary source. The inclusion of this information herein does not authorize any reuse or further distribution without the expressed, written permission of Springer SBM, on behalf of the AJCC.

Version 2.2015, 01/15/15 © National Comprehensive Cancer Network, Inc. 2015, All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®.

黑色素細胞癌(melanoma)

附件一-2:

National Comprehensive Cancer Network®

NCCN Guidelines Version 2.2015 Staging Melanoma

NCCN Guidelines Index
Melanoma Table of Contents
Discussion

Distant Metastasis (M)

M0	No detectable evidence of distant metastases
M1a	Metastases to skin, subcutaneous, or distant lymph nodes
M1b	Metastases to lung
M1c	Metastases to all other visceral sites or distant metastases to any site combined with an elevated serum LDH

Note: Serum LDH is incorporated into the M category as shown below:

M Classification	*Site*	*Serum LDH*
M1a	Distant skin, subcutaneous, or nodal mets	Normal
M1b	Lung metastases	Normal
M1c	All other visceral metastases	Normal
	Any distant metastasis	Elevated

Anatomic Stage/Prognostic Groups

Clinical Staging*

Stage 0	Tis	N0	M0
Stage IA	T1a	N0	M0
Stage IB	T1b	N0	M0
	T2a	N0	M0
Stage IIA	T2b	N0	M0
	T3a	N0	M0
Stage IIB	T3b	N0	M0
	T4a	N0	M0
Stage IIC	T4b	N0	M0
Stage III	AnyT	≥N1	M0
Stage IV	Any T	Any N	M1

*Clinical staging includes microstaging of the primary melanoma and clinical/radiologic evaluation for metastases. By convention, it should be used after complete excision of the primary melanoma with clinical assessment for regional and distant metastases.

Pathologic Staging**

Stage 0	Tis	N0	M0
Stage IA	T1a	N0	M0
Stage IB	T1b	N0	M0
	T2a	N0	M0
Stage IIA	T2b	N0	M0
	T3a	N0	M0
Stage IIB	T3b	N0	M0
	T4a	N0	M0
Stage IIC	T4b	N0	M0
Stage IIIA	T(1–4)a	N1a	M0
	T(1–4)a	N2a	M0
Stage IIIB	T(1–4)b	N1a	M0
	T(1–4)b	N2a	M0
	T(1–4)a	N1b	M0
	T(1–4)a	N2b	M0
	T(1–4)a	N2c	M0
Stage IIIC	T(1–4)b	N1b	M0
	T(1–4)b	N2b	M0
	T(1–4)b	N2c	M0
	Any T	N3	M0
Stage IV	Any T	Any N	M1

**Pathologic staging includes microstaging of the primary melanoma and pathologic information about the regional lymph nodes after partial or complete lymphadenectomy. Pathologic Stage 0 or Stage IA patients are the exception; they do not require pathologic evaluation of their lymph nodes.

Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original and primary source for this information is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer Science+Business Media, LLC (SBM). (For complete information and data supporting the staging tables, visit www.springer.com.) Any citation or quotation of this material must be credited to the AJCC as its primary source. The inclusion of this information herein does not authorize any reuse or further distribution without the expressed, written permission of Springer SBM, on behalf of the AJCC.

Version 2.2015, 01/15/15 © National Comprehensive Cancer Network, Inc. 2015, All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®.

黑色素細胞癌(melanoma)

高雄榮民總醫院
臨床診療指引 2015第一版

附件二:

National Comprehensive Cancer Network®

NCCN Guidelines Version 2.2015
Melanoma

NCCN Guidelines Index
Melanoma Table of Contents
Discussion

PRINCIPLES OF SURGICAL MARGINS FOR WIDE EXCISION OF PRIMARY MELANOMA

Tumor Thickness	Recommended Clinical Margins[2]
In situ[1]	0.5-1.0 cm
≤1.0 mm	1.0 cm (category 1)
1.01-2 mm	1-2 cm (category 1)
2.01-4 mm	2.0 cm (category 1)
>4 mm	2.0 cm (category 1)

- **Margins may be modified to accommodate individual anatomic or functional considerations.**

[1]For large melanoma in situ (MIS), lentigo maligna type, surgical margins >0.5 cm may be necessary to achieve histologically negative margins; techniques for more exhaustive histologic assessment of margins should be considered. For selected patients with positive margins after optimal surgery, consider topical imiquimod (for patients with MIS) or RT (category 2B).
[2]Excision recommendations are based on measured clinical margins taken at the time of surgery and not gross or histologic margins, as measured by the pathologist (category 1).

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

Version 2.2015, 01/15/15 © National Comprehensive Cancer Network, Inc. 2015, All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®.

黑色素細胞癌(melanoma)

高雄榮民總醫院
臨床診療指引 2015第一版

附件三：

National Comprehensive Cancer Network®

NCCN Guidelines Version 2.2015
Melanoma

NCCN Guidelines Index
Melanoma Table of Contents
Discussion

PRINCIPLES OF RADIATION THERAPY FOR MELANOMA

Consider RT in the following situations:[1]

PRIMARY DISEASE

- Adjuvant treatment in selected patients with factors including, but not limited to deep desmoplastic melanoma with narrow margins, extensive neurotropism or locally recurrent disease.

REGIONAL DISEASE[2]

- Adjuvant treatment in selected patients following resection of clinically appreciable nodes (category 2B)[3] if
  - LDH <1.5 x upper limit of normal AND
  - Extranodal tumor extension AND/OR
    - Parotid: ≥1 involved node, any size of involvement
    - Cervical: ≥2 involved nodes and/or ≥3 cm tumor within a node
    - Axillary: ≥2 involved nodes and/or ≥4 cm tumor within a node
    - Inguinal: ≥3 involved nodes and/or ≥4 cm tumor within a node
- Palliative
  - Unresectable nodal, satellite, or in-transit disease

METASTATIC DISEASE

- Brain metastases (see NCCN Guidelines for Central Nervous System Cancers)
  - Stereotactic radiosurgery either as adjuvant or primary treatment
  - Whole brain radiation therapy, either as adjuvant (category 2B) or primary treatment[4]
- Other symptomatic or potentially symptomatic soft tissue and/or bone metastases[2]

[1]Interactions between radiation therapy and systemic therapies (eg, *BRAF* inhibitors and interferon alfa-2b) need to be very carefully considered as there is potential for increased toxicity.
[2]A wide range of radiation dose/fractionation schedules is effective. Hypofractionated regimens may increase the risk for long-term complications.
[3]Adjuvant nodal basin RT is associated with reduced lymph node field recurrence but has no impact on relapse-free or overall survival, and its benefits must be weighed against the increased probability of long-term skin and regional toxicities and potential reduced quality of life.
[4]Adjuvant whole brain radiation following resected melanoma brain metastasis is controversial and should be considered on an individual patient basis. An ongoing randomized clinical trial (ANZMTG 01-07, ACTRN12607000512426, NCT01503827) is currently investigating adjuvant whole brain radiation (Fogarty G, Morton RL, Vardy J, et al. Whole brain radiotherapy after local treatment of brain metastases in melanoma patients--a randomised phase III trial. BMC Cancer. 2011;17:142.)

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

Continue

Version 2.2015, 01/15/15 © National Comprehensive Cancer Network, Inc. 2015, All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®.

黑色素細胞癌(melanoma)

高雄榮民總醫院
臨床診療指引 2015第一版

附件四-1:CVD regimen

化學治療處方

CVD regimen	
published C/T regimens	**schedule**
Dacarbazine 800mg/m2, IV, D1	**Q28d * 6 cycles**
Cisplatin 20mg/m2, IV, D2-5	**Q28d * 6 cycles**
Vinblastine 1.6mg/m2, IV, D1-5	**Q28d * 6 cycles**



黑色素細胞癌(melanoma)

附件四-2:CVD regimen, CCr < 60

化學治療處方

CVD regimen, CCr < 60	
published C/T regimens	**schedule**
Dacarbazine 800mg/m2, IV, D1	**Q28d * 6 cycles**
Vinblastine 1.6mg/m2, IV, D1-5	**Q28d * 6 cycles**
Paraplatin auc*1.25mg, IV, D2-5	**Q28d * 6 cycles**



黑色素細胞癌(melanoma)

附件五-1：Dartmouth regimen (Odd)

化學治療處方

Dartmouth regimen (Odd)	
published C/T regimens	**schedule**
Carmustine 150mg/m2, IV, D1	**Q28d * 6 cycles**
Dacarbazine 220mg/m2, IV, D1-3	**Q28d * 6 cycles**
Cisplatin 25mg/m2, IV, D1-3	**Q28d * 6 cycles**
Nolvadex 10mg, PO, D1-3	**Q28d * 6 cycles**



黑色素細胞癌(melanoma)

高雄榮民總醫院
臨床診療指引 2015第一版

附件五-2：Dartmouth regimen (Even)

化學治療處方

Dartmouth regimen (Even)	
published C/T regimens	**schedule**
Dacarbazine 220mg/m2, IV, D1-3	**Q28d * 6 cycles**
Cisplatin 25mg/m2, IV, D1-3	**Q28d * 6 cycles**
Nolvadex 10mg, PO, D1-3	**Q28d * 6 cycles**



黑色素細胞癌(melanoma)

附件五-3：Dartmouth regimen (Odd), CCr < 60

化學治療處方

Dartmouth regimen (Odd), CCr < 60	
published C/T regimens	**schedule**
Carmustine 150mg/m2, IV, D1-3	**Q28d * 6 cycles**
Dacarbazine 220mg/m2, IV, D1-3	**Q28d * 6 cycles**
Paraplatin auc*1.6mg, IV, D1-3	**Q28d * 6 cycles**
Nolvadex 10mg, PO, D1-3	**Q28d * 6 cycles**



黑色素細胞癌(melanoma)

高雄榮民總醫院
臨床診療指引 2015第一版

附件五-4：Dartmouth regimen (Even),CCr < 60

化學治療處方

Dartmouth regimen (Even),CCr < 60	
published C/T regimens	**schedule**
Dacarbazine 220mg/m2, IV, D1-3	**Q28d * 6 cycles**
Paraplatin auc*1.6mg, IV, D1-3	**Q28d * 6 cycles**
Nolvadex 10mg, PO, D1-3	**Q28d * 6 cycles**



黑色素細胞癌(melanoma)

高雄榮民總醫院
臨床診療指引 2015第一版

附件六：melanoma with brain metastasis

化學治療處方

melanoma with brain metastasis	
published C/T regimens	**schedule**
Temodal 150mg/m2/, IV, D1-5	**Q28d * 6 cycles**



Reference

1. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009;27:6199-6206.
2. Piris A, Mihm MC, Jr., Duncan LM. AJCC melanoma staging update: impact on dermatopathology practice and patient management. J Cutan Pathol 2011;38:394-400.
3. Gimotty PA, Elder DE, Fraker DL, et al. Identification of high-risk patients among those diagnosed with thin cutaneous melanomas. J Clin Oncol 2007;25:1129-1134.
4. Bichakjian CK, Halpern AC, Johnson TM, et al. Guidelines of care for the management of primary cutaneous melanoma. American Academy of Dermatology. J Am Acad Dermatol 2011;65:1032-1047.
5. College of American Pathologists. Protocol for the Examination of Specimens from Patients with Melanoma of the Skin. 2013.
6. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001;19:3622-3634.
7. Cascinelli N, Belli F, Santinami M, et al. Sentinel lymph node biopsy in cutaneous melanoma: the WHO Melanoma Program experience. Ann Surg Oncol 2000;7:469-474.
8. Yancovitz M, Finelt N, Warycha MA, et al. Role of radiologic imaging at the time of initial diagnosis of stage T1b-T3b melanoma. Cancer 2007;110:1107-1114.
9. Pandalai PK, Dominguez FJ, Michaelson J, Tanabe KK. Clinical value of radiographic staging in patients diagnosed with AJCC stage III melanoma. Ann Surg Oncol 2011;18:506-513.
10. Schroer-Gunther MA, Wolff RF, Westwood ME, et al. F-18-fluoro-2-deoxyglucose positron emission tomography (PET) and PET/computed tomography imaging in primary staging of patients with malignant melanoma: a systematic review. Syst Rev 2012;1:62.
11. Veronesi U, Cascinelli N, Adamus J, et al. Thin stage I primary cutaneous malignant melanoma. Comparison of excision with margins of 1 or 3 cm. N Engl J Med 1988;318:1159-1162.
12. Khayat D, Rixe O, Martin G, et al. Surgical margins in cutaneous melanoma (2 cm versus 5 cm for lesions measuring less than 2.1-mm thick). Cancer 2003;97:1941-1946.
13. Gillgren P, Drzewiecki KT, Niin M, et al. 2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2 mm: a randomised, multicentre trial. Lancet 2011.
14. Thomas JM, Newton-Bishop J, A'Hern R, et al. Excision margins in high-risk malignant melanoma. N Engl J Med 2004;350:757-766.
15. Haigh PI, DiFronzo LA, McCready DR. Optimal excision margins for primary cutaneous melanoma: a systematic review and meta-analysis.Can J Surg 2003;46:419-426 Kunishige JH, Brodland DG, Zitelli JA. Surgical margins for melanoma in situ. J Am Acad Dermatol 2012;66:438-444.
16. Kunishige JH, Brodland DG, Zitelli JA. Surgical margins for melanoma in situ. J Am Acad Dermatol 2012;66:438-444.
17. Farshad A, Burg G, Panizzon R, Dummer R. A retrospective study of 150 patients with lentigo maligna and lentigo maligna melanoma and the efficacy of radiotherapy using Grenz or soft X-rays. Br J Dermatol 2002;146:1042-1046.



Reference

18. Johnson TM, Sondak VK, Bichakjian CK, Sabel MS. The role of sentinel lymph node biopsy for melanoma: evidence assessment. J Am Acad Dermatol 2006;54:19-27.
19. Coit DG, Brennan MF. Extent of lymph node dissection in melanoma of the trunk or lower extremity. Arch Surg 1989;124:162-166.
20. Hancock BW, Wheatley K, Harris S, et al. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma. J Clin Oncol 2004;22:53-61.
21. Petrella T, Verma S, Spithoff K, et al. Adjuvant interferon therapy for patients at high risk for recurrent melanoma: an updated systematic review and practice guideline. Clin Oncol (R Coll Radiol) 2012;24:413-423.
22. Agrawal S, Kane JM, 3rd, Guadagnolo BA, et al. The benefits of adjuvant radiation therapy after therapeutic lymphadenectomy for clinically advanced, high-risk, lymph node-metastatic melanoma. Cancer 2009;115:5836-5844.
23. Hofmann M, Kiecker F, Wurm R, et al. Temozolomide with or without radiotherapy in melanoma with unresectable brain metastases. J Neurooncol 2006;76:59-64.
24. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711- 723.
25. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-2516.
26. Hauschild A, Grob JJ, Demidov LV, et al. Phase III, randomized, open-label, multicenter trial (BREAK-3) comparing the BRAF kinase inhibitor dabrafenib (GSK2118436) with dacarbazine (DTIC) in patients with BRAFV600E-mutated melanoma [abstract]. J Clin Oncol 2012;30(Suppl18):LBA8500.
27. Long GV, Trefzer U, Davies MA, et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 2012;13:1087-1095.
28. Kim KB, Kefford R, Pavlick AC, et al. Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAFmutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol 2013;31:482-489.
29. Guo J, Si L, Kong Y, et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol 2011;29:2904-2909.
30. Serrone L, Zeuli M, Sega FM, Cognetti F. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. J Exp Clin Cancer Res 2000;19:21-34.
31. Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000;18:158-166.
32. Rosenberg SA, Yang JC, Topalian SL, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 1994;271:907-913.
33. Eigentler TK, Caroli UM, Radny P, Garbe C. Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. Lancet Oncol 2003;4:748-759.
34. Atkins M, Hsu J, Lee S, et al. Phase III Trial Comparing Concurrent Biochemotherapy With Cisplatin, Vinblastine, Dacarbazine, Interleukin-2, and Interferon Alfa-2b With Cisplatin, Vinblastine, and Dacarbazine. Alone in Patients With Metastatic Malignant Melanoma (E3695): A Trial Coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2008;26:5748-5754.